This website has been produced and funded by Novo Nordisk and is intended for adult patients in
United Kingdom who have been prescribed Wegovy®▼ (semaglutide injection). Side effect reporting
information can be found in the footer of this page.
Welcome to the Wegovy®▼(semaglutide injection) website
This website is here to support your journey with Wegovy® — a once-weekly injectable medicine that is prescribed to adult patients, in addition to diet and physical activity, to help with:
At Novo Nordisk, our mission is to help create a healthier world by addressing some of the most pressing threats to public health—including obesity, diabetes, and cardiovascular disease.
Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible for those who need them most. We currently have no plans of changing our offering in the UK.
This is not a real patient and is for illustrative purposes only.
Optimising your journey with Wegovy®
Wegovy® is just one part of your treatment journey. Healthy lifestyle choices can also play a role in managing your health. Discover guidance on how to make changes to your lifestyle that could help you to get the most out of your treatment.
Additional support and information
To support the information and care provided by your healthcare team, you can also access a suite of resources on this website, including:
- Wegovy® information booklets — support brochures for people who are taking Wegovy®
- How-to-use guides — illustrated guidance on how to use your Wegovy® FlexTouch® pen
- A printable and downloadable dosing calendar — a calendar to help you keep track of your treatment and dose changes
If you have any questions about your treatment, remember your healthcare team is there to support and advise you.
This is not a real patient or healthcare professional and is for illustrative purposes only.
Do you have a specific question about your treatment?
The ‘Frequently Asked Questions (FAQs)’ section of this website provides answers to common questions that people can have when starting on Wegovy®.
If you have a specific question in mind, visit the FAQs page. If you can’t find the answer you’re looking for, you may find it helpful to write down your question so that you remember to ask your healthcare team at your next appointment.
The information on this website does not replace the Patient Information Leaflet (PIL), which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice. Please refer to the PIL found in the product carton for further information on Wegovy®, further information on how to use Wegovy®and a full list of side effects, warnings and precautions.
Reporting side effects
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.